奥施康定治疗中重度癌痛临床观察

目的：观察盐酸羟考酮控释片（奥施康定）治疗中重度癌痛的疗效及不良反应。方法：采用开放试验方法，对49例中重度癌痛患者进行治疗。奥施康定起始剂量10mg／12h，根据疼痛缓解程度调整剂量，评价镇痛效果、KPS评分及不良反应。结果：49例中重度癌痛患者，平均镇痛时间12．45h。总有效率89．80％，中度疼痛组有效率93．75％，重度疼痛组有效率87．88％。KPS评分：28例（57．14％）升高，19例（38．78％）稳定，2例（4．08％）病情恶化死亡。不良反应主要为便秘7例（14．29％）。结论：奥施康定治疗中重度癌痛疗效确切，不良反应轻，服用安全。

Clinical observation of oxycontin in management of moderate and severe cancer pain

Objective： To observe analgesic effect and main side effects of oxycontin in management of the moderate and severe cancer pain. Methods：Foyrtynine patients with moderate and severe cancer pain were selected. Oxyeontin was administered at an initial dose of 10mg every 12h and titrated upwards according to the extent of pain relief. Outcomes included analgesic effect, Karnofsky Performance Status Scales （ KPS ） and side effect. Results ： Among all the 49 patients the mean duration of analgesic effect was 12.45h, total effective rate was 89.80% , effective rate of the moderate and severe cancer pain was 93.75% and 87.88% , respectively. KPS was elevated in 28 patients （ 57.14% ） and stable in 19（38.78% ） after application of oxycontin,2 patients（4.08% ） died. Main adverse effect was constipation in 7 patients（ 14.29% ）. Conclusion：Oxyeontin is safe and effective and with slight adverse effects in treatment of moderate and sever cancer pain.